MedTrace Logo

Vasoactive Drugs in Intensive Care Unit

NCT02118467 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 836

Last updated 2026-01-13

No results posted yet for this study

Summary

The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind controlled trial comparing phenylephrine and vasopressin vs. norepinephrine and epinephrine in ICU patients with shock that is not responsive to IV fluids. All patients admitted to the adult intensive care units at the University of Chicago will be screened for eligibility.

Conditions

  • Shock

Interventions

DRUG

Norepinephrine

Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.

DRUG

Epinephrine

Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.

DRUG

Phenylephrine

Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.

DRUG

Vasopressin

Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • John P Kress, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-15
Primary Completion
2026-10-01
Completion
2026-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02118467 on ClinicalTrials.gov